Maria Τektonidou: TMN Manifestation Scores and Mortality in Antiphospholipid Syndrome
Maria Τektonidou, Professor of Rheumatology at National and Kapodistrian University of Athens, shared a post on LinkedIn, about a recent article she and her colleagues co-authored, adding:
“Further Validation of the Eular Antiphospholipid syndrome disease activity score (Eapsdas). Criterion Validity using mortality as the criterion.
The maximum scores of thrombotic/microvascular/non-thrombotic (TMN) manifestations were significantly higher among patients who died due to Antiphospholipid Syndrome than among those who survived and those who died from other causes”
Title: Criterion validity of the EULAR Antiphospholipid Syndrome Disease Activity Score (EAPSDAS)
Authors: Maria G. Tektonidou, Ricard Cervera , Guillermo J. Pons-Estel , Savino Sciascia, Angela Tincani , Michael M. Ward
Read the Full Article on Annals of the Rheumatic Diseases
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin